April 20, 2016 / 11:22 AM / a year ago

BRIEF-Aralez says conducted bioequivalence studies comparing Aspirin from old and new suppliers

1 Min Read

April 20 (Reuters) - Aralez Pharmaceuticals Inc

* Conducted human bioequivalence studies comparing aspirin drug manufactured from original aspirin supplier to new primary aspirin supplier

* Aralez Pharmaceuticals Inc says bioequivalence studies tested both 81 mg and 325 mg Yosprala doses

* Aralez says study data demonstrated aspirin in Yosprala formulated from original supplier was bioequivalent to that of new primary supplier

* Aralez says worked directly with new primary aspirin supplier to help prepare it for a previously planned inspection by FDA

* Aralez Pharmaceuticals Inc says FDA inspection has recently concluded and did not result in any reported compliance findings Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below